Loading...
A recent meta-analysis (Journal Watch May 24 2007) found that rosiglitazone increased the risk for cardiovascular death (by 64%) and for myocardial infarction (by 43%). The authors of that meta-analysis acknowledged numerous limitations. Investigators present a reanalysis, focusing on two additional methodologic limitations — concerns about combining results from heterogeneous study designs and subject populations, and concerns about the use of a method of meta-analysis that excluded studies with no events in either randomized group.
In a reanalysis that addresses the concern about the choice of the meta-analytic method, the increase in risk for cardiovascular death associated with rosiglitazone (17%–51% across several different analyses) wa…